Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 160928, 11 pages
http://dx.doi.org/10.1155/2015/160928
Review Article

Emerging Role of PACAP as a New Potential Therapeutic Target in Major Diabetes Complications

1Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
2Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
3Semel Institute, Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA

Received 12 January 2015; Revised 31 March 2015; Accepted 7 April 2015

Academic Editor: Janaka Karalliedde

Copyright © 2015 Rubina Marzagalli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. King, R. E. Aubert, and W. H. Herman, “Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections,” Diabetes Care, vol. 21, no. 9, pp. 1414–1431, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Donnelly, A. M. Emslie-Smith, I. D. Garnder, and A. D. Morris, “ABC of arterial and venous disease. Vascular complications of diabetes,” British Medical Journal, vol. 320, no. 7241, pp. 1062–1066, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Nathan, P. A. Cleary, J.-Y. C. Backlund et al., “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2643–2653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Casanova, F. J. Hughes, and P. M. Preshaw, “Diabetes and periodontal disease: a two-way relationship,” British Dentistry Journal, vol. 217, no. 8, pp. 433–437, 2014. View at Publisher · View at Google Scholar
  6. L. Feng, C. Matsumoto, A. Schwartz, A. M. Schmidt, D. M. Stern, and J. Pile-Spellman, “Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis,” Diabetes Care, vol. 28, no. 2, pp. 379–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Crimi, L. J. Ignarro, and C. Napoli, “Microcirculation and oxidative stress,” Free Radical Research, vol. 41, no. 12, pp. 1364–1375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Miyata, A. Arimura, R. R. Dahl et al., “Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells,” Biochemical and Biophysical Research Communications, vol. 164, no. 1, pp. 567–574, 1989. View at Publisher · View at Google Scholar · View at Scopus
  9. N. M. Sherwood, S. L. Krueckl, and J. E. McRory, “The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily,” Endocrine Reviews, vol. 21, no. 6, pp. 619–670, 2000. View at Publisher · View at Google Scholar
  10. M. Laburthe, A. Couvineau, and J.-C. Marie, “VPAC receptors for VIP and PACAP,” Receptors and Channels, vol. 8, no. 3-4, pp. 137–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Elekes, K. Sandor, A. Moricz et al., “Pituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory role in endotoxin-induced airway inflammation: in vivo study with gene-deleted mice,” Peptides, vol. 32, no. 7, pp. 1439–1446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Reglodi, P. Kiss, K. Szabadfi et al., “PACAP is an endogenous protective factor-insights from PACAP-deficient mice,” Journal of Molecular Neuroscience, vol. 48, no. 3, pp. 482–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Castorina, A. Tiralongo, S. Giunta, M. L. Carnazza, G. Rasi, and V. D'Agata, “PACAP and VIP prevent apoptosis in schwannoma cells,” Brain Research, vol. 1241, pp. 29–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Giunta, A. Castorina, A. Adorno, V. Mazzone, M. L. Carnazza, and V. D'Agata, “PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells,” Neuropeptides, vol. 44, no. 1, pp. 45–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Castorina, S. Giunta, S. Scuderi, and V. D'Agata, “Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells,” Journal of Molecular Neuroscience, vol. 48, no. 3, pp. 674–683, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Castorina, J. A. Waschek, R. Marzagalli, V. Cardile, F. Drago, and H. Vaudry, “PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like cultures,” PLOS ONE, vol. 10, no. 2, Article ID e0117799, 2015. View at Publisher · View at Google Scholar
  17. S. Giunta, A. Castorina, R. Marzagalli et al., “Ameliorative effects of PACAP against cartilage degeneration. Morphological, immunohistochemical and biochemical evidence from in vivo and in vitro models of rat osteoarthritis,” International Journal of Molecular Sciences, vol. 16, no. 3, pp. 5922–5944, 2015. View at Publisher · View at Google Scholar
  18. V. D'Agata and S. Cavallaro, “Functional and molecular expression of PACAP/VIP receptors in the rat retina,” Molecular Brain Research, vol. 54, no. 1, pp. 161–164, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Somogyvári-Vigh, J. Svoboda-Teet, S. Vigh, and A. Arimura, “Is an intravenous bolus injection required prior to initiating slow intravenous infusion of PACAP38 for prevention of neuronal death induced by global ischemia? The possible presence of a binding protein for PACAP38 in blood,” Annals of the New York Academy of Sciences, vol. 865, pp. 595–600, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Shioda, H. Ohtaki, T. Nakamachi et al., “Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment,” Annals of the New York Academy of Sciences, vol. 1070, pp. 550–560, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Ohtaki, T. Nakamachi, K. Dohi, and S. Shioda, “Role of PACAP in ischemic neural death,” Journal of Molecular Neuroscience, vol. 36, no. 1–3, pp. 16–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Winzell and B. Ahrén, “Role of VIP and PACAP in islet function,” Peptides, vol. 28, no. 9, pp. 1805–1813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Broca, J. Quoyer, S. Costes et al., “β-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic β-cells,” The Journal of Biological Chemistry, vol. 284, no. 7, pp. 4332–4342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Ødum, L. J. Petersen, P. S. Skov, and L. B. Ebskov, “Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells,” Inflammation Research, vol. 47, no. 12, pp. 488–492, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Heimesaat, I. R. Dunay, S. Schulze et al., “Pituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelae,” PLoS ONE, vol. 9, no. 9, Article ID e108389, 2014. View at Publisher · View at Google Scholar
  26. H. Terubayashi, T. Tsuto, K. Fukui et al., “VIP (vasoactive intestinal polypeptide)-like immunoreactive amacrine cells in the retina of the rat,” Experimental Eye Research, vol. 36, no. 5, pp. 743–749, 1983. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Izumi, T. Seki, S. Shioda, C.-J. Zhou, A. Arimura, and R. Koide, “Ultrastructural localization of PACAP immunoreactivity in the rat retina,” Annals of the New York Academy of Sciences, vol. 921, pp. 317–320, 2000. View at Google Scholar · View at Scopus
  28. T. Seki, S. Izumi, S. Shioda, C. J. Zhou, A. Arimura, and R. Koide, “Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR,” Annals of the New York Academy of Sciences, vol. 921, pp. 366–369, 2000. View at Google Scholar · View at Scopus
  29. K. Moller, Y.-Z. Zhang, R. Hakanson et al., “Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence,” Neuroscience, vol. 57, no. 3, pp. 725–732, 1993. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Mulder, R. Uddman, K. Moller et al., “Pituitary adenylate cyclase activating polypeptide expression in sensory neurons,” Neuroscience, vol. 63, no. 1, pp. 307–312, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Onali and M. C. Olianas, “PACAP is a potent and highly effective stimulator of adenylyl cyclase activity in the retinas of different mammalian species,” Brain Research, vol. 641, no. 1, pp. 132–134, 1994. View at Publisher · View at Google Scholar · View at Scopus
  32. Z.-Y. Wang, P. Alm, and R. Håkanson, “Distribution and effects of pituitary adenylate cyclase-activating peptide in the rabbit eye,” Neuroscience, vol. 69, no. 1, pp. 297–308, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Seki, S. Shioda, D. Ogino, Y. Nakai, A. Arimura, and R. Koide, “Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina,” Neuroscience Letters, vol. 238, no. 3, pp. 127–130, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Seki, S. Shioda, Y. Nakai, A. Arimura, and R. Koide, “Distribution and ultrastractural localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor in the rat retina,” Annals of the New York Academy of Sciences, vol. 865, pp. 408–411, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Seki, Y. Hinohara, C. Taki et al., “PACAP stimulates the release of interleukin-6 in cultured rat Müller cells,” Annals of the New York Academy of Sciences, vol. 1070, pp. 535–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Di Paolo, L. Gesualdo, E. Ranieri, G. Grandaliano, and F. P. Schena, “High glucose concentration induces the overexpression of transforming growth factor-β through the activation of a platelet-derived growth factor loop in human mesangial cells,” The American Journal of Pathology, vol. 149, no. 6, pp. 2095–2106, 1996. View at Google Scholar · View at Scopus
  37. H. Ogita and J. K. Liao, “Endothelial function and oxidative stress,” Endothelium, vol. 11, no. 2, pp. 123–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. O. I. Stenina, “Regulation of vascular genes by glucose,” Current Pharmaceutical Design, vol. 11, no. 18, pp. 2367–2381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Ribatti, M. T. Conconi, and G. G. Nussdorfer, “Nonclassic endogenous regulators of angiogenesis,” Pharmacological Reviews, vol. 59, no. 2, pp. 185–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Castorina, S. Giunta, V. Mazzone, V. Cardile, and V. D'Agata, “Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells,” Peptides, vol. 31, no. 12, pp. 2276–2283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. R.-C. Hilaire, S. N. Murthya, P. J. Kadowitza, and J. R. Jeter Jr., “Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation,” Peptides, vol. 31, no. 8, pp. 1517–1522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Garlanda, C. Parravicini, M. Sironi et al., “Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7291–7295, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Rácz, B. Gasz, B. Borsiczky et al., “Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis,” General and Comparative Endocrinology, vol. 153, no. 1–3, pp. 115–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Hultgårdh-Nilsson, J. Nilsson, B. Jonzon, and C.-J. Dalsgaard, “Growth-inhibitory properties of vasoactive intestinal polypeptide,” Regulatory Peptides, vol. 22, no. 3, pp. 267–274, 1988. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Mazzocchi, L. K. Malendowicz, G. Neri et al., “Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland,” International Journal of Molecular Medicine, vol. 9, no. 3, pp. 233–243, 2002. View at Google Scholar · View at Scopus
  46. L. Åkesson, B. Ahrén, G. Edgren, and E. Degerman, “VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes,” Endocrinology, vol. 146, no. 2, pp. 744–750, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. C. J. Rhodes, “Type 2 diabetes—a matter of β-cell life and death?” Science, vol. 307, no. 5708, pp. 380–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. E. Thomas and T. J. Biden, “Bad news for β-cell apoptosis,” Diabetes, vol. 58, no. 8, pp. 1725–1727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Mathis, L. Vence, and C. Benoist, “β-cell death during progression to diabetes,” Nature, vol. 414, no. 6865, pp. 792–798, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. R. P. Robertson and J. S. Harmon, “Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet β cell,” Free Radical Biology and Medicine, vol. 41, no. 2, pp. 177–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. G. M. Portela-Gomes, A. Lukinius, O. Ljungberg, S. Efendic, B. Ahrén, and S. M. Abdel-Halim, “PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas: evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets,” Regulatory Peptides, vol. 113, no. 1–3, pp. 31–39, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Inagaki, H. Yoshida, M. Mizuta et al., “Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 7, pp. 2679–2683, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Yada, M. Sakurada, H. Ishihara et al., “Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats,” Journal of Physiology, vol. 505, no. 2, pp. 319–328, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Yamamoto, H. Hashimoto, S. Tomimoto et al., “Overexpression of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes,” Diabetes, vol. 52, no. 5, pp. 1155–1162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Onoue, J. Hanato, and S. Yamada, “Pituitary adenylate cyclase-activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression,” The FEBS Journal, vol. 275, no. 22, pp. 5542–5551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Vaudry, A. Falluel-Morel, S. Bourgault et al., “Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery,” Pharmacological Reviews, vol. 61, no. 3, pp. 283–357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Sakurai, N. Shintani, A. Hayata, H. Hashimoto, and A. Baba, “Trophic effects of PACAP on pancreatic islets: a mini-review,” Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 3–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Ahrén, “Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system,” Annals of the New York Academy of Sciences, vol. 1144, pp. 28–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. N. G. Congdon, D. S. Friedman, and T. Lietman, “Important causes of visual impairment in the world today,” Journal of the American Medical Association, vol. 290, no. 15, pp. 2057–2060, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Williams, M. Airey, H. Baxter, J. Forrester, T. Kennedy-Martin, and A. Girach, “Epidemiology of diabetic retinopathy and macular oedema: a systematic review,” Eye, vol. 18, no. 10, pp. 963–983, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. Q. Mohamed, M. C. Gillies, and T. Y. Wong, “Management of diabetic retinopathy: a systematic review,” Journal of the American Medical Association, vol. 298, no. 8, pp. 902–916, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Kolár, “Patophysiology of diabetic retinopathy,” Vnitřní lékařství, vol. 59, no. 3, pp. 173–176, 2013. View at Google Scholar
  63. D. A. Antonetti, A. J. Barber, S. K. Bronson et al., “Diabetic retinopathy: seeing beyond glucose-induced microvascular disease,” Diabetes, vol. 55, no. 9, pp. 2401–2411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Zhang, N. Wang, G. R. Barile, S. Bao, and M. Gillies, “Diabetic retinopathy: neuron protection as a therapeutic target,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 7, pp. 1525–1529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Gábriel, “Neuropeptides and diabetic retinopathy,” British Journal of Clinical Pharmacology, vol. 75, no. 5, pp. 1189–1201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Giunta, A. Castorina, C. Bucolo, G. Magro, F. Drago, and V. D'Agata, “Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats,” Peptides, vol. 37, no. 1, pp. 32–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Szabadfi, T. Atlasz, P. Kiss et al., “Protective effects of the neuropeptide PACAP in diabetic retinopathy,” Cell and Tissue Research, vol. 348, no. 1, pp. 37–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Szabadfi, A. Szabo, P. Kiss et al., “PACAP promotes neuron survival in early experimental diabetic retinopathy,” Neurochemistry International, vol. 64, no. 1, pp. 84–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Somogyvári-Vigh and D. Reglodi, “Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide,” Current Pharmaceutical Design, vol. 10, no. 23, pp. 2861–2889, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Seaborn, O. Masmoudi-Kouli, A. Fournier, H. Vaudry, and D. Vaudry, “Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis,” Current Pharmaceutical Design, vol. 17, no. 3, pp. 204–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Scuderi, A. G. D'Amico, A. Castorina, R. Imbesi, M. L. Carnazza, and V. D'Agata, “Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction,” Peptides, vol. 39, no. 1, pp. 119–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. C. E. Mogensen, C. K. Christensen, and E. Vittinghus, “The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy,” Diabetes, vol. 32, no. 2, pp. 64–78, 1983. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Gnudi, “Cellular and molecular mechanisms of diabetic glomerulopathy,” Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2642–2649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Banki, K. Kovacs, D. Nagy et al., “Molecular mechanisms underlying the nephroprotective effects of PACAP in diabetes,” Journal of Molecular Neuroscience, vol. 54, no. 3, pp. 300–309, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Reglodi, P. Kiss, G. Horvath et al., “Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney,” Neuropeptides, vol. 46, no. 2, pp. 61–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Banki, P. Degrell, P. Kiss et al., “Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy,” Peptides, vol. 42, pp. 125–130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993.
  79. N. A. Calcutt, M. E. Cooper, T. S. Kern, and A. M. Schmidt, “Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials,” Nature Reviews Drug Discovery, vol. 8, no. 5, pp. 417–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. B. D. Green, N. Irwin, and P. R. Flatt, “Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential,” Peptides, vol. 27, no. 6, pp. 1349–1358, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Li, J. L. Maderdrut, J. J. L. Lertora, and V. Batuman, “Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study,” Peptides, vol. 28, no. 9, pp. 1891–1895, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Yu, J. Wang, J. Li et al., “A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes,” Peptides, vol. 31, no. 6, pp. 1062–1067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Cheng, Y. Ding, R. Yu, J. Chen, C. Wu, and R. Linden, “Neuroprotection of a novel cyclopeptide C*HSDGIC* from the cyclization of PACAP (1–5) in cellular and rodent models of retinal ganglion cell apoptosis,” PLoS ONE, vol. 9, no. 10, Article ID e108090, 2014. View at Publisher · View at Google Scholar
  84. B. D. Green, N. Irwin, N. A. Duffy, V. A. Gault, F. P. M. O'Harte, and P. R. Flatt, “Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1,” European Journal of Pharmacology, vol. 547, no. 1–3, pp. 192–199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Ahrén and T. E. Hughes, “Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice,” Endocrinology, vol. 146, no. 4, pp. 2055–2059, 2005. View at Publisher · View at Google Scholar · View at Scopus